Specificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human Cells

Carfilzomib (CFZ) is a second-generation proteasome inhibitor that is Food and Drug Administration and European Commission approved for the treatment of relapsed or refractory multiple myeloma. CFZ is an epoxomicin derivative with an epoxyketone electrophilic warhead that irreversibly adducts the ca...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Cell Proteomics
Hlavní autoři: Federspiel, Joel D., Codreanu, Simona G., Goyal, Sandeep, Albertolle, Matthew E., Lowe, Eric, Teague, Juli, Wong, Hansen, Guengerich, F. Peter, Liebler, Daniel C.
Médium: Artigo
Jazyk:Inglês
Vydáno: The American Society for Biochemistry and Molecular Biology 2016
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5054346/
https://ncbi.nlm.nih.gov/pubmed/27503896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/mcp.M116.059709
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky